Huadong Medicine

CompanyChina

Huadong Medicine develops 2 assets, the furthest in phase 2 (HDM1002 in obesity). Mostly small molecule and peptide acting on GLP1R and GIPR; based in China.

2
Assets
Furthest stage: Phase 2; 0
Trials: 2
Signals

Pipeline

2

HDM1002
Activates GLP-1 receptors to promote satiety and reduce body weight.
Phase 2, Small molecule, GLP1R, obesity, overweight
HDM1005
Long-acting dual GLP-1 and GIP receptor agonist promoting weight loss and improving glycemic control.
Phase 2, Peptide, GLP1R, GIPR, obesity

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms4
Deals21
Signals4
Similar companies6

Papers

Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Efficacy and Safety of Dual GLP-1/GIP Receptor Agonist HDM1005 in Obese Participants without Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study
ADA Scientific Sessions 2025 abstract, 13 Jun 2025